Wize Pharma (Israel) Performance

WIZP -- Israel Stock  

ILS 213.00  10.20  5.03%

The firm maintains market beta of -27.71 which attests that as returns on market increase, returns on owning Wize Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Wize Pharma is expected to significantly outperform it. Although it is extremely important to respect Wize Pharma historical price patterns, it is better to be realistic regarding the information on equity current price history. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By examining Wize Pharma technical indicators you can presently evaluate if the expected return of 0.0% will be sustainable into the future. Wize Pharma right now maintains a risk of 0.0%. Please check out Wize Pharma Semi Deviation, Coefficient Of Variation and the relationship between Mean Deviation and Downside Deviation to decide if Wize Pharma will be following its historical returns.
Horizon     30 Days    Login   to change

Wize Pharma Relative Risk vs. Return Landscape

If you would invest  21,300  in Wize Pharma on February 23, 2019 and sell it today you would earn a total of  0.00  from holding Wize Pharma or generate 0.0% return on investment over 30 days. Wize Pharma is generating negative expected returns and assumes 0.0% volatility on return distribution over the 30 days horizon. Simply put, 0% of equities are less volatile than Wize Pharma and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 

Wize Pharma Market Risk Analysis

Sharpe Ratio = 0.0
Good Returns
Average Returns
Small Returns
Based on monthly moving average Wize Pharma is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Wize Pharma by adding it to a well-diversified portfolio.

Wize Pharma Performance Rating

Wize Pharma Risk Adjusted Performance Analysis


Risk-Adjusted Performance

Over the last 30 days Wize Pharma has generated negative risk-adjusted returns adding no value to investors with long positions.

Wize Pharma Alerts

Equity Alerts and Improvement Suggestions

Wize Pharma is not yet fully synchronised with the market data
Wize Pharma generates negative expected return over the last 30 days
Wize Pharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company has accumulated 707K in total debt with debt to equity ratio (D/E) of 217.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Wize Pharma has Current Ratio of 0.23 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported revenue of . Net Loss for the year was (1.91M).
WIZE PHARMA has accumulated about 275K in cash with (1.1M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.

Wize Pharma Performance Indicators

Wize Pharma Basic Price Performance Measures

Fifty Two Week Low190.40
Fifty Two Week High218.00
See also Your Current Watchlist. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Search macroaxis.com